AI
ADAP

Atom Investors’s Adaptimmune Therapeutics ADAP Stock Holding History

Atom Investors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,510
Closed -$16.6K – 464
2024
Q1 		$16.6K Buy
+10,510
New +$12.7K ﹤0.01% 558

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Atom Investors's ADAP Position: Q2 2024 in Review

Atom Investors sold out of Adaptimmune Therapeutics (ADAP) in Q2 2024, closing a stake of 10,510 shares — an estimated $16.6K sold.

Atom Investors first reported a position in ADAP in Q1 2024 and held it in 1 quarter. The position peaked at $16.6K in Q1 2024. 76 funds tracked by Wall St. Rank hold ADAP as of Q2 2024.

  • Atom Investors reported no remaining Adaptimmune Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Atom Investors sold 10,510 Adaptimmune Therapeutics shares in Q2 2024, an estimated $16.6K.
  • Atom Investors first reported a position in Adaptimmune Therapeutics in Q1 2024 and held it in 1 quarter.
  • Atom Investors's Adaptimmune Therapeutics position peaked at $16.6K in Q1 2024.
  • 76 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2024.

Based on Atom Investors's 13F filing for Q2 2024, filed 14 Aug 2024.